Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer

Hamaguchi, 2002, DBC2, a candidate for a tumor-suppressor gene involved in breast cancer, Proc Natl Acad Sci USA, 99, 13647, 10.1073/pnas.212516099

Cha, 2009, Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma, Clin Cancer Res, 15, 4453, 10.1158/1078-0432.CCR-08-3329

Sung, 2010, Balance between SIRT1 and DBC1 expression is lost in breast cancer, Cancer Sci, 101, 1738, 10.1111/j.1349-7006.2010.01573.x

Lee, 2011, Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma, Hum Pathol, 42, 204, 10.1016/j.humpath.2010.05.023

Kim, 2008, DBC1 is a negative regulator of SIRT1, Nature, 451, 583, 10.1038/nature06500

Zhao, 2008, Negative regulation of the deacetylase SIRT1 by DBC1, Nature, 451, 587, 10.1038/nature06515

Sundararajan, 2005, Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-alpha-mediated death signaling, Oncogene, 24, 4908, 10.1038/sj.onc.1208681

Hiraike, 2010, Identification of DBC1 as a transcriptional repressor for BRCA1, Br J Cancer, 102, 1061, 10.1038/sj.bjc.6605577

Koyama, 2010, Repression of estrogen receptor beta function by putative tumor suppressor DBC1, Biochem Biophys Res Commun, 392, 357, 10.1016/j.bbrc.2010.01.025

Blander, 2004, The Sir2 family of protein deacetylases, Annu Rev Biochem, 73, 417, 10.1146/annurev.biochem.73.011303.073651

Huffman, 2007, SIRT1 is significantly elevated in mouse and human prostate cancer, Cancer Res, 67, 6612, 10.1158/0008-5472.CAN-07-0085

Kabra, 2009, SirT1 is an inhibitor of proliferation and tumor formation in colon cancer, J Biol Chem, 284, 18210, 10.1074/jbc.M109.000034

Jang, 2009, Expression and prognostic significance of SIRT1 in ovarian epithelial tumours, Pathology, 41, 366, 10.1080/00313020902884451

Zhang, 2009, Deacetylation of cortactin by SIRT1 promotes cell migration, Oncogene, 28, 445, 10.1038/onc.2008.388

Vaziri, 2001, hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase, Cell, 107, 149, 10.1016/S0092-8674(01)00527-X

Wong, 2007, Deacetylation of the retinoblastoma tumour-suppressor protein by SIRT1, Biochem J, 407, 451, 10.1042/BJ20070151

Oberdoerffer, 2008, SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging, Cell, 135, 907, 10.1016/j.cell.2008.10.025

Japanese Pathological Response Criteria of Breast Cancer, 2008, General Rules for Clinical and Pathological Recording of Breast Cancer, 75

Kurosumi, 2008, Histopatho-logical criteria for assessment of therapeutic response in breast cancer (2007 version), Breast Cancer, 15, 5, 10.1007/s12282-007-0016-x

Harvey, 1999, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer, J Clin Oncol, 17, 1474, 10.1200/JCO.1999.17.5.1474

Carey, 2006, Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, JAMA, 295, 2492, 10.1001/jama.295.21.2492

Tsuda, 1998, Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section, Jpn J Clin Oncol, 28, 486, 10.1093/jjco/28.8.486

Trauernicht, 2007, Modulation of estrogen receptor alpha protein level and survival function by DBC-1, Mol Endocrinol, 21, 1526, 10.1210/me.2007-0064

Richardson, 2006, X chromosomal abnormalities in basal-like human breast cancer, Cancer Cell, 9, 121, 10.1016/j.ccr.2006.01.013